KR101728386B1 - Composition for enhancing immune activity comprising milk protein with high content of organic zinc as an active ingredient and preparation method thereof - Google Patents

Abstract

The zinc oxide-enriched milk protein, which is prepared by mixing water with a mixture of whey powder and water-soluble zinc powder, not only enhances the bioavailability of minerals, but also orally administers one of them to the macrophages macrophage), neutropenia (neutrophil), mononuclear (monocyte) increase the number of pathogenic microorganisms invading a primary immune cells and natural killer (NK) cell resistant to the and the like, CD4-positive T _H cells in blood or lymph nodes (helper (TNF-α) and interleukin (TNF-α), which are immuno-related cytokines secreted from activated macrophages and promote the number of T-cell and CD8-positive T _C cells (cytotoxic T- -1β (IL-1β) and exhibits an immunostimulating activity, it can be used as an active ingredient of a food composition for immunostimulating or a composition for improving immunity

Description

[0001] The present invention relates to a composition for enhancing immunity comprising an organic zinc rich milk protein as an active ingredient and a method for preparing the same,

The present invention relates to a composition for enhancing immunity comprising an organotinized zinc-rich milk protein as an active ingredient. The composition for enhancing immunity can be used as an active ingredient of a food composition for immunostimulation or a pharmaceutical composition for enhancing immunity.

Korean Patent No. 1025272 discloses that the bioavailability of organic minerals such as calcium, iron, selenium and zinc, including hydrolyzed sericin and its associated minerals, is significantly better than that of inorganic minerals.

Korean Patent No. 1306931 discloses that an organic calcium-enriched milk protein obtained by heat-treating a mixture of non-sterilized whey and water-soluble calcium has excellent bioavailability and thus exhibits osteoporosis prevention and therapeutic effects.

However, the inventive zinc oxide-fortified milk protein or calcium oxide-fortified milk protein prepared by mixing the whey powder with the water-soluble zinc or calcium powder and then heat-treating the present invention not only promotes the bioavailability of the mineral, The number of immune cells and natural killer (NK) cells that primarily resist the invasion of pathogenic microorganisms such as macrophages, neutrophils, monocytes and the like in the blood is increased, CD4-positive in the lymph node T _H cells (helper T-cell) and CD8-positive T _C cells sikimyeo increase the number of (cytotoxic T-cell), activated macrophages (activated macrophage) immune-related cytokine tumor necrosis factor secreted from -α (TNF-α) and interleukin-1β (IL-1β), and thus the present invention has been completed.

It is an object of the present invention to provide a composition for enhancing immunity comprising an organotin-zinc-fortified milk protein as an active ingredient.

It is another object of the present invention to provide a method for producing an organo zincated milk protein having an immunostimulating activity.

In order to attain the above object, the present invention provides a method for producing zinc oxide or calcium-enriched milk protein prepared by adding water to a mixed powder obtained by mixing whey powder and water-soluble zinc or calcium powder and heating at 70 to 100 ° C for 10 minutes to 40 hours As an effective ingredient.

The whey powder may be a non-demineralized whey powder or a demineralized whey powder.

The water-soluble zinc or calcium powder may be a sulfate or a chloride of zinc or calcium.

The composition for enhancing immunity may be a food composition for enhancing immunity or a pharmaceutical composition for enhancing immunity.

The present invention also relates to a method for producing a fermented milk, comprising the steps of: mixing whey powder and water-soluble zinc or calcium powder; And adding water to the mixed powder and heating at 70 to 100 ° C for 10 minutes to 40 hours. The present invention also provides a method for producing zinc oxide or calcium-enriched milk protein having an immunostimulating activity.

The zincated or calcium-enriched milk protein of the present invention can be used to treat immune cells and natural killer (NK) cells that primarily resist invasion of pathogenic microorganisms such as macrophages, neutrophils, monocytes, increasing the number of and, in the blood or lymph node sikimyeo increase the number of CD4-positive T _H cells (helper T-cell) and CD8-positive T _C cells (cytotoxic T-cell), which is secreted by the activated macrophages (activated macrophage) (TNF-a) and interleukin-l [beta] (IL-l [beta]), which are immunomodulatory cytokines, and exhibit immunostimulatory activity.

FIG. 1A is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in blood of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1B is a graph showing the distribution of CD8 T cells in blood of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1C is a graph showing the distribution of CD4 T cells in the blood of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1D is a graph showing the distribution of NK cells and NKT cells in blood of a mouse administered with calcium-enriched calcium-rich milk (Ca-WPS) by a flow cytometer (FACS).
FIG. 1E is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in a lymph node of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1F is a graph comparing secretion amounts of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice treated with calcium-enriched calcium-rich milk (Ca-WPS), with inorganic calcium and whey powder (WPS).
2A is a graph showing the distribution of macrophages, neutrophils, and mononuclear cells in blood of a mouse administered with zinc oxide-enriched milk protein (Zn-WPS) by flow cytometry (FACS).
FIG. 2B is a graph showing the distribution of NK cells and NKT cells in blood of a mouse administered with zinc oxide-enriched milk protein (Zn-WPS) by a flow cytometer (FACS).
FIG. 2C is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in a lymph node of a mouse administered with zinc oxide-enriched milk protein (Zn-WPS) by a flow cytometer (FACS).
FIG. 2d is a graph showing the distribution of CD8 T cells in a lymph node of a mouse administered with zinc oxide-enriched milk protein (Zn-WPS) by a flow cytometer (FACS).
FIG. 2E is a graph showing the distribution of CD4 T cells in a lymph node of a mouse administered with zinc oxide-enriched milk protein (Zn-WPS) by a flow cytometer (FACS).
FIG. 2f is a graph comparing secretion amounts of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice treated with zinc oxide-enriched milk protein (Zn-WPS), with inorganic zinc and whey powder (WPS).

Hereinafter, the present invention will be described in detail.

The present invention relates to a method for improving the immune enhancement using an organotin zinc or calcium-enriched milk protein prepared by adding water to a mixed powder obtained by mixing a whey powder and a water-soluble zinc or calcium powder and heating the mixture at 70 to 100 ° C for 10 minutes to 40 hours The present invention also relates to a process for preparing a mixture of whey powder and water-soluble zinc or calcium powder; And adding water to the mixed powder and heating at 70 to 100 ° C for 10 minutes to 40 hours. The present invention also relates to a method for producing zinc oxide or calcium-fortified milk protein having immunostimulatory activity.

The whey powder may be a non-demineralized whey powder or a demineralized whey powder. The milk protein content of the whey powder is 10 to 20% by weight. For example, the milk protein content may vary depending on the kind of the raw material, the manufacturing method and the manufacturer, but generally 12 to 15% by weight of the non-desalted whey powder and 14 to 17% by weight of the demineralized whey powder are included.

The water-soluble zinc or calcium powder may be a sulfate or a chloride of zinc or calcium. For example, the water-soluble zinc powder may be zinc sulfate powder and the water-soluble calcium powder may be calcium chloride powder.

When chlorides or sulfates are used as the water-soluble zinc or calcium powder, the content of chlorine ions or sulfate ions increases as the organotinized zinc or calcium increases. These increased chlorine ions or sulfate ions can be simply removed by washing with water. For example, the concentration of the sulfate ion can be lowered to a harmless level through 1-5 repeated washing with 0.5 to 10 times water, preferably 1 to 2 times, of the volume of water used to dissolve the zinc sulfate have. The washing can be carried out by adding a suitable amount of water and centrifuging to remove the supernatant, for example, centrifuging at 500 to 50,000 rpm for 1 to 60 minutes. The centrifugation is carried out at room temperature without setting a temperature condition , But can be performed by setting the temperature constant to 25 DEG C or lower.

The mixing ratio of the whey powder and the water-soluble zinc or calcium powder may be adjusted according to the content of zinc oxide or calcium organotissue in the organochydinized zinc or calcium-enriched milk protein to be produced. For example, 1 to 100 parts by weight of water-soluble zinc or calcium powder may be mixed with 100 parts by weight of whey powder.

The amount of water to be mixed with the mixed powder of the whey powder and the water-soluble zinc or calcium powder may be adjusted to an amount required to dissolve the mixed powder, for example, 200 to 1500 parts by weight may be mixed with 100 parts by weight of the whey powder .

After adding water to the mixed powder, the mixture is stirred at 100 to 500 rpm for 5 to 60 minutes to dissolve, and then the mixture is heated at 70 to 100 ° C, preferably at 80 to 90 ° C for 10 minutes to 40 hours, And heated for 60 minutes to prepare zinc oxide or calcium-fortified milk protein.

The composition for enhancing immunity may be a food composition for enhancing immunity or a pharmaceutical composition for enhancing immunity.

As used herein, the term " comprising as an active ingredient " means that the inventive copper or iron-enriched hardened protein of the present invention contains an amount sufficient to exhibit immunostimulatory activity. The composition for immune enhancement of the present invention is preferably, but not limited to, 0.1 to 50% by weight of the above-described zinc oxide or calcium-enriched milk protein, based on the total weight of the composition.

The pharmaceutical composition for enhancing immunity of the present invention can be utilized as an adjuvant for treating cancer diseases or vaccines for immunization which is required for immunotherapy.

The pharmaceutical compositions may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of medicaments.

The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods. Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be formulated into the compositions of the present invention with at least one excipient such as starch, calcium carbonate, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.

The pharmaceutical composition may be administered orally or parenterally. Any parenteral administration method may be used, and systemic administration or topical administration is possible, but systemic administration is more preferable, and intravenous administration is most preferable.

The preferred dosage of the pharmaceutical composition will vary depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition may be administered at a dose of 0.01 to 200 占 퐂 / kg per day, preferably 1 to 20 占 퐂 / kg, based on the recommended amount of copper or iron, based on the content of copper or iron good. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the composition of the present invention can be used as a food composition for an assisted diet of a cancer patient as well as a general person including an elderly person who needs immunity enhancing activity.

In the above food composition, there is no particular limitation on the kind of food. Examples of foods to which the above substances can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.

The zinc oxide or calcium-fortified milk protein can be added directly to the food or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

In the case of producing a drink, there are no particular restrictions on the other components other than those containing the above-described zinc oxide or calcium-enriched milk protein as an essential ingredient in the indicated ratios, and various flavors or natural carbohydrates, . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 of the composition of the present invention.

In addition to the above, the organotinized zinc or calcium-rich milk protein of the present invention can be used as a nutritional supplement, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and intermediates such as cheese and chocolate, Alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, the inventive zincated or calcium-enriched milk proteins may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples. However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples and Production Examples.

Preparation Example 1: Preparation of organotinized minerals

The non-desalted whey powder (hereinafter referred to as "WPS", 14% by weight protein) of Lacto Korea was used as the whey powder, and calcium chloride (CaCl 2 .H 2 O), calcium chloride Zinc sulfate (ZnSO 4 · 5H 2 O) was used for the production of organic zinc oxide.

The WPS and inorganic minerals were mixed in a weight ratio of 5: 1 so as to be mixed well. Then, distilled water having twice the weight of WPS was added thereto four times, followed by vigorous reaction for 30 minutes, followed by heating to 80 DEG C and reaction at 150 rpm for 30 minutes. After the reaction was completed, the reaction mixture was cooled at room temperature, centrifuged at 4000 rpm for 20 minutes at 25 ° C, and the supernatant was removed. The precipitate was washed three times with water of about 3 times the volume of the precipitate. The washed precipitate was spray dried and pulverized. Ca-WPS and zinc-enriched milk proteins were named as Zn-WPS and Ca-WPS, respectively.

Experimental Example 1: Mineral analysis of organic-mineralized milk-fortified milk protein

The mineral content of Preparation Example 1 was analyzed by ICP method and shown in Table 1.

division WPS Ca-WPS Zn-WPS Calcium (ppm) 3,111 38,880 12,560 Copper (ppm) ND 0.44 5.53 Iron (ppm) 1.3 25 12 Zinc (ppm) ND 3.55 15,190 Selenium (ppm) ND ND ND

* ND is not detected

EXPERIMENTAL EXAMPLE 2: Confirmation of Immune Enhancement Effect by Animal Experiment

1. Breeding and classification of experimental animals

Five week old Balb / C male rats (ORIENTBIO Inc., Korea) were purchased and weighed and weighed. The body weight was divided into five groups, WPS group and organically fortified mineral fortified milk protein group. Organic mineralized fortified milk protein was divided into high concentration, medium concentration and low concentration by concentration. 3 ~ 4 rabbits were kept at 20.0 ~ 25.0 ℃ temperature, 41.2 ~ 58.5% relative humidity and 150 ~ 300Lux light intensity. And they were kept in accordance with the Guideline for Breeding of Chonnam National University Medical School.

2. Organic mineral fortified milk protein dosage determination

The daily intake of minerals according to the Food and Drug Administration's safety standards is shown in Table 2.

division Adult (based on 60kg) Mouse (based on 20g) calcium 210-800 mg 70-266 [mu] g zinc 3.6-12 mg 1.2-4 [mu] g

The high concentration, medium concentration and low concentration were calculated in consideration of the minerals content of the organo-mineralized milk-derived milk protein of Table 1 within the range not exceeding the standard of the above-mentioned food service administration, and the intake per kg per kg , The daily intakes of the mice were calculated on the basis of the body weight of 20 g, and the daily dose of the mice was determined as shown in Table 3.

division WPS Ca-WPS Zn-WPS High concentration 260 [mu] g 260 [mu] g 4 [mu] g Medium concentration - 168 [mu] g 2.4 [mu] g Low concentration - 70 [mu] g 0.85 [mu] g

3. Experimental Method

1) Feed

Feeds were fed with animal feed (Rodent diet 2918C; Harlan Teklad, Indianapolis, IN, USA) and diet and beverages were fed free. Body weights were measured twice before the start of treatment and after 6 weeks.

2) Blood collection and tissue extraction

Each group was anesthetized with isoflurane and the blood was collected from the abdominal vein. Blood was collected and lymph nodes were collected.

3) Immunocytochemical analysis of blood

The blood sample is by 5 minutes centrifugation at 500 xg separate the serum, the control did not stain by dividing each one by 1x10 ⁶ cells using a hemacytometer, CD3, CD122, CD8a, and stained with CD4 marker antibodies and flow cytometry (FACSAria) Were used for immunocytochemical analysis. During flow cytometry, living cells were gated to measure cells stained with live intracellular marker antibodies. The macrophage, neutrophil and mononuclear cell distribution is the area indicated by the red arrow in the unstained sample.

In addition, NK cells and NKT cells were analyzed by gating P4 labeled on unstained samples. NK cells are distributed on the upper left side, and NKT cells are on the upper right side.

4) Immunocytochemical analysis of lymph nodes

The collected lymph nodes were carefully dissected from the mesh of 100 pore size to separate the cells. The cells were separated by centrifugation and counted with a hemacytometer. The cells were stained with 1 × 10 ⁶ cells in each well and stained with non-stained control, CD3, CD122, CD8a, CD4 marker antibody and analyzed by immunocytochemistry using a flow cytometer (FACSAria) In flow cytometry, living cells were gated to measure cells stained with a living intracellular marker antibody.

5) Measurement of cytokine secretion ability

(IL-1β, TNF-α) secreted from the culture supernatant were measured after the intraperitoneal macrophages were orally administered to the mice, which were orally administered with the mineral minerals, WPS, and the organo-mineralized milk protein. Non-adherent cells were removed and only adherent cells were obtained and cultured in 10% -FBS RPMI 1640, 37 ° C, 5% CO2 incubator (Sanyo) for 48 hours. The amount of IL-1β and TNF-α accumulated in the culture supernatant was measured by ELISA cytokine kit (R & Dsystem, USA).

4. Experimental results

1) Distribution of macrophages, neutrophils and mononuclear cells in blood

The macrophage, neutrophil, and monocyte populations in the blood of mice treated with calcium-enriched calcium-rich milk (Ca-WPS) did not show any significant difference compared to mice administered with WPS only, .

The macrophage, neutrophil, and monocyte populations of mice treated with Zinc-fortified milk protein (Zn-WPS) were significantly different from those of mice treated with WPS alone. In the groups administered with 4 ㎍ and 2.4 ㎍ of 0.85 ㎍, (Fig. 2A).

2) Distribution of CD8 and CD4-positive T cells in blood

The CD8 + T cell population in the blood of mice treated with calcium-enriched calcium-rich milk (Ca-WPS) was significantly higher than that of mice treated with WPS only, but no difference was observed in the high and low dose groups (FIG. 1b) The CD4 + cell population also increased in the CD4 + T cell population compared to the WPS-only mice (FIG. 1c).

2) NK cell distribution of blood

The distribution of NK cells and NKT cells in the blood of mice treated with calcium-enriched calcium-rich milk (Ca-WPS) showed no significant difference compared to mice administered with WPS alone, and there was no difference in concentration (Fig. 1 ).

In the group treated with zinc oxide-enriched milk protein (Zn-WPS), there was no significant difference in NKT cells compared with the group treated with WPS only, but it was increased in the NK cell population (FIG. 2B).

3) Distribution of macrophages, neutrophils and monocytes in lymph nodes

The macrophage, neutrophil, and monocyte populations of the lymphocytes treated with calcium-enriched Ca-enhanced milk protein (Ca-WPS), as well as blood, did not show any significant difference compared to mice administered with WPS only (FIG.

(Zn-WPS) group compared to mice treated with WPS alone (Fig. 2c).

4) Distribution of CD8 and CD4-positive T cells in lymph nodes

The CD8 + T cell population was not significantly different from the WPS-only mice (Fig. 2d), but the CD4 + T cell population was increased (Fig. 2e) in the group treated with zinc oxide-enriched milk protein (Zn-WPS) CD8 ratio increased.

5) IL-1β and TNF-α secretion of macrophages

As a result of the secretion amount of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice administered with calcium-enriched calcium-enriched milk protein (Ca-WPS), mice treated with calcium- The amount of cytokine secretion tended to be higher than that of mice administered only (Fig. 1F).

The secretion of cytokines TNF-a and IL-1b was markedly increased in mice treated with zinc oxide-enriched milk protein (Zn-WPS) and mice treated with inorganic zinc or WPS alone (Fig. 2f).

The formulation examples of the present invention are described below, but are for the purpose of illustration only and not for purposes of limitation of the present invention.

≪ Formulation Example 1 > Preparation of pharmaceutical preparation

1-1. Manufacture of Powder

500 mg of the organotin-zinc-fortified milk protein of Preparation Example 1

Lactose 100 mg

10 mg of talc

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

500 mg of the organotin-enhanced calcium-enriched milk protein of Preparation Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Manufacture of capsules

500 mg of the organotin-zinc-fortified milk protein of Preparation Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Production Example 2: Preparation of health functional food (powder type)

1000 mg of the organotin-enhanced calcium-enriched milk protein of Preparation Example 1

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 mg of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Production Example 3: Preparation of health functional foods (beverage type)

1000 mg of the organotin-zinc-fortified milk protein of Preparation Example 1

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 liter container, And used for manufacturing.

Although the composition ratio is relatively mixed with the ingredient suitable for the favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand class, demand country, use purpose, and the like.

Production Example 4: Preparation of health functional foods (chewing gum)

Gum base 20%

Sugar 76.36 ~ 76.76%

The organotin-enhanced calcium-enriched milk protein of Preparation Example 1 0.24 to 0.64%

Fruit flavor 1%

Water 2%

Chewing gum was prepared using the above-mentioned composition and content by a conventional method.

Preparation Example 5: Preparation of health functional foods (wheat flour foods)

0.5 to 5 parts by weight of the zinc oxide-enriched milk protein of Preparation Example 1 was added to 100 parts by weight of wheat flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare health improving foods.

Production Example 6: Preparation of health functional foods (dairy products)

5 to 10 parts by weight of the organotin-enhanced calcium-enriched milk protein of Preparation Example 1 was added to 100 parts by weight of milk, and various dairy products such as butter and ice cream were prepared using the milk.

Claims (5)

delete delete delete delete Powder mixing the whey powder and the water soluble zinc powder; And adding water to the mixed powder and heating the mixture at 70 to 100 ° C for 10 minutes to 40 hours.

Images